Bringspring Science and Technology Co (300290) Fair Value & Analysis
Technology · CN · Market cap 6.3B CNY
Fair value as of: Jul 9, 2026
From 8 valuation models · updated today
Share price −59.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥4.20 – ¥32.01 · fair‑value band ¥0.4700 – ¥0.6200 · the ¥4.20 price screens above the ¥0.5000 fair value. As of Jul 9, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Bringspring Science and Technology Co (300290) currently trades at ¥4.20, while our model-based Fair Value estimate is ¥0.5000 — implying the stock looks roughly 88.1% overvalued today. We read business quality at 36/100 (below-average quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Bringspring Science and Technology Co generated revenue of 741M CNY at a net margin of -5.0%. Revenue declined 11.5% year over year. It earns a return on equity of -3.3%. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥0.4700 (bear case) to ¥0.6200 (bull case); at ¥4.20, the current price sits above that range. For context, the median of 10 Technology peers we cover trades at 9% fair-value upside — at -88%, 300290 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 9, 2026. TTM = trailing twelve months.
About the company
Bringspring Science and Technology Co., Ltd. primarily engages in the smart healthcare business in China. It operates through Health Care and Social Security, Government and Public Utilities, and Others segments. The company's smart medical records services include medical record statistics management, integrated medical records, medical record tracing, digital medical records, paperless medical record management, micro medical records, and self-service printing terminals. Its DRG/DIP services also comprise DRG medical insurance operation supervision systems, DRG medical service operation supervision systems, medical insurance settlement list reporting, and DIP medical insurance operation supervision systems; and medical quality control services include medical record homepage quality control system, medical insurance intelligent review system, medical insurance settlement list management system, and full-process medical record quality control system. In addition, the company's …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bringspring Science and Technology Co reported revenue of ¥755M in FY2025 versus ¥817M in FY2021, a compound −2.0%/yr. Reported net income was −¥45.1M in FY2025.
Is 300290 fairly valued? → Check now
Similar stocks
10 more Information Technology Services stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| International Business Machines Corporation IBM | $264.94 | $147.06 | -44% |
| Accenture plc ACN | $124.83 | $250.14 | +100% |
| Tata Consultancy Services Limited TCS | ₹2,060 | ₹2,590 | +26% |
| Infosys Limited INFY | ₹1,198 | ₹1,237 | +3% |
| HCL Technologies Limited HCLTECH | ₹1,132 | ₹1,230 | +9% |
| Fiserv, Inc F1IS34 | R$138.35 | R$187.39 | +35% |
| Cognizant Technology Solutions Corporation CTSH34 | R$216.10 | R$93.61 | -57% |
| Wipro Limited WIPRO | ₹178.93 | ₹226.94 | +27% |
| Fidelity National Information Services, Inc F1NI34 | R$12.14 | R$1.22 | -90% |
| Broadridge Financial Solutions, Inc B1RF34 | R$190.00 | R$180.05 | -5% |
Explore undervalued stocks
More undervalued Technology stocks →
Frequently asked questions
Is Bringspring Science and Technology Co (300290) undervalued?
What is the fair value of 300290?
What is the quality score of 300290?
What is the revenue of Bringspring Science and Technology Co (300290)?
What is the net profit margin of 300290?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.